Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 243 publications
Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison.
Journal: Leukemia & lymphoma
Published: July 10, 2026
A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma.
Journal: Current medical research and opinion
Published: June 25, 2026
Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.
Journal: Haematologica
Published: March 12, 2026
Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: February 24, 2026
Timing and Pattern of Extraosseous Dissemination Are Key Determinants of Survival in Multiple Myeloma.
Journal: American journal of hematology
Published: February 09, 2026
Baseline absolute lymphocyte count, C-reactive protein, and ferritin predict CAR T cell-related toxicities and outcomes in multiple myeloma.
Journal: Bone marrow transplantation
Published: January 21, 2026
Environmental exposures and multiple myeloma risk: A contemporary review of epidemiologic associations and mechanistic plausibility.
Journal: Blood reviews
Published: November 24, 2025
Healthcare resource utilization and costs in patients with multiple myeloma who received 1 to 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, and were exposed to and discontinued lenalidomide in the United States.
Journal: Journal of medical economics
Published: November 03, 2025
Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses.
Journal: Clinical lymphoma, myeloma & leukemia
Published: September 23, 2025
Last Updated: 09/26/2026